Oncotelic Therapeutics OTLC

Oncotelic Therapeutics, Inc. is a clinical stage biopharmaceutical company developing drugs for the treatment of cancer. The company focuses on translating its expertise in RNA therapeutics into antisense therapies targeting TGF-β overexpression. Its lead product candidate, OT-101, is being developed as a broad-spectrum anti-cancer agent for difficult-to-treat cancers such as gliomas and pancreatic cancer. The company conducts research and development through wholly-owned subsidiaries and a joint venture with GMP Biotechnology Limited.

Oncotelic Therapeutics, Inc. generates revenue primarily through licensing agreements, strategic partnerships, and service contracts related to its proprietary technologies. The company has entered into partnerships such as the one with Shanghai Medicilon, Inc. to support investigational new drug applications and with TechForce Robotics, Inc. to advance a GMP-compliant robotics platform integrating its PDAOAI technology. Additionally, the company recognizes revenue from intellectual property development and services agreements, including the agreement with Lunai Bioworks, Inc. for a Nose-to-Brain delivery platform.

The company operates through the following segments:

• RNA Therapeutics: This segment focuses on the development of antisense oligonucleotides targeting TGF-β overexpression for oncology and other diseases. The lead asset in this segment is OT-101, which has demonstrated clinical activity in phase 2 trials for gliomas and pancreatic cancers. The segment also includes preclinical development of OT-101 for Duchenne Muscular Dystrophy and other indications.
• Nanoparticle Platform: This segment involves the formulation of water-insoluble drugs using proprietary nanoparticle sizes to improve drug delivery and absorption. The platform, also referred to as the Deciparticle™ platform, is being used to develop injectable formulations of drugs such as everolimus, palbociclib, docetaxel, paclitaxel, and carboplatin. The segment is supported by more than 15 patent families covering chemical composition, manufacturing, and method of use.
• PDAOAI Platform: This segment encompasses the company’s proprietary artificial intelligence–enabled knowledge platform designed for pharmaceutical and biotechnology applications. PDAOAI supports scientific research, biomarker discovery, and regulatory documentation across the oncology pipeline. The platform has been used to generate peer-reviewed publications and is integrated into workflows for target identification, biomarker strategy, clinical trial design, and regulatory positioning. It is designed to generate hypotheses traceable to underlying evidence for validation and regulatory acceptance.

Oncotelic Therapeutics, Inc. operates in the highly competitive biopharmaceutical industry, specifically within the oncology and precision medicine sectors. The company differentiates itself through its proprietary RNA therapeutic platform targeting TGF-β, its nanoparticle delivery technology, and its AI-driven PDAOAI system. While it faces competition from larger pharmaceutical companies developing cancer therapies, its focus on novel mechanisms and platform technologies provides a distinct competitive advantage in early-stage development.

Oncotelic Therapeutics, Inc. serves patients with oncological conditions, particularly those suffering from gliomas, pancreatic cancer, lung cancer, and mesothelioma. The company also targets patients with neurodegenerative disorders such as Alzheimer’s disease through its Nose-to-Brain delivery platform. Additionally, its technologies are intended for use by pharmaceutical manufacturers and research institutions requiring GMP-compliant automation and AI-enabled compliance workflows.